Clinical Trial Detail

NCT ID NCT04164069
Title Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Anne Noonan
Indications

colorectal cancer

Therapies

Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior adult

No variant requirements are available.